Acorn Capital Advisors, LLC Puma Biotechnology, Inc. Transaction History
Acorn Capital Advisors, LLC
- $144 Billion
- Q1 2025
A detailed history of Acorn Capital Advisors, LLC transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Acorn Capital Advisors, LLC holds 3,940,052 shares of PBYI stock, worth $13.9 Million. This represents 8.12% of its overall portfolio holdings.
Number of Shares
3,940,052
Previous 2,450,711
60.77%
Holding current value
$13.9 Million
Previous $12 Billion
2.95%
% of portfolio
8.12%
Previous 6.31%
Shares
2 transactions
Others Institutions Holding PBYI
# of Institutions
117Shares Held
31MCall Options Held
32.7KPut Options Held
200-
Vanguard Group Inc Valley Forge, PA3.67MShares$12.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$12.6 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.01MShares$7.07 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.83MShares$6.44 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.39MShares$4.88 Million0.0% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $160M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...